Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential intravesical mitomycin-C and gemcitabine in high-risk NMIBC unresponsive to BCG
KCT0009491Phase 2
Key facts
- Status
- Recruiting
- Start
- Nov 2024
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Conditions
- non-muscle-invasive bladder cancer (NMIBC)
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c and gemcitabine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Nov 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Sequential intravesical mitomycin-C + gemcitabine
Single treatment arm receiving sequential intravesical mitomycin-C followed by gemcitabine for high-risk non-muscle invasive bladder cancer unresponsive to BCG.
03
Who it enrols
Adult patients in Korea with high-risk non-muscle invasive bladder cancer that is unresponsive to prior intravesical BCG therapy.
Beyond the preview
Go deeper on KCT0009491.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009491.